| Year |
Citation |
Score |
| 2023 |
Janganati V, Salazar P, Parks BJ, Gorman GS, Prather PL, Peterson EC, Alund AW, Moran JH, Crooks PA, Brents LK. Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats. Frontiers in Pharmacology. 14: 1123261. PMID 37229250 DOI: 10.3389/fphar.2023.1123261 |
0.755 |
|
| 2022 |
Cabanlong CV, Russell LN, Fantegrossi WE, Prather PL. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. Toxicological Sciences : An Official Journal of the Society of Toxicology. PMID 35201352 DOI: 10.1093/toxsci/kfac024 |
0.331 |
|
| 2020 |
Penthala NR, Shoeib A, Dachavaram SS, Cabanlong CV, Yang J, Zhan CG, Prather PL, Crooks PA. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands. Bioorganic & Medicinal Chemistry Letters. 30: 127501. PMID 32882418 DOI: 10.1016/J.Bmcl.2020.127501 |
0.48 |
|
| 2020 |
Pinson A, Yarbrough AL, Bush JM, Cabanlong CV, Shoeib A, Jackson BK, Fukuda S, Gogoi J, Fantegrossi WE, McCain K, Prather PL, Fujiwara R, Radominska-Pandya A. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacology, Biochemistry, and Behavior. 172949. PMID 32413436 DOI: 10.1016/J.Pbb.2020.172949 |
0.692 |
|
| 2020 |
Jones S, Yarbrough AL, Fantegrossi WE, Prather PL, Bush JM, Radominska-Pandya A, Fujiwara R. Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). Pharmacology Research & Perspectives. 8: e00561. PMID 32003945 DOI: 10.1002/Prp2.561 |
0.658 |
|
| 2019 |
Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced tolerance and asymmetrical cross-tolerance to effects of indole quinuclidinone analogue PNR-4-20, a G protein biased CB1R agonist in mice: comparisons with Δ9-THC and JWH-018. The Journal of Pharmacology and Experimental Therapeutics. PMID 30833484 DOI: 10.1124/Jpet.118.252965 |
0.697 |
|
| 2019 |
Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic Analysis of Glucuronidation of Synthetic Cannabinoid 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-25. PMID 30739533 DOI: 10.1080/00498254.2019.1580403 |
0.648 |
|
| 2019 |
Yarbrough AL, Pinson A, Prather PL, Fantegrossi WE, Bush JM, Fujiwara R, Radominska-Pandya A. Oxidative Metabolism and Comparative Analysis of Synthetic Cannabinoid N-(1-adamantyl)-1-(5-fluoropentyl)indazole-3-carboxamide (5F-AKB-48) and the Unfluorinated Analog AKB-48 The Faseb Journal. 33. DOI: 10.1096/Fasebj.2019.33.1_Supplement.469.6 |
0.614 |
|
| 2019 |
Yarbrough A, Fujiwara R, Fantegrossi W, Prather P, Radominska-Pandya A. Oxidative metabolism of synthetic cannabinoid STS-135 by recombinant P450S and human liver microsomes Drug Metabolism and Pharmacokinetics. 34: S28. DOI: 10.1016/J.Dmpk.2018.09.111 |
0.606 |
|
| 2018 |
Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL. Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ-THC. Frontiers in Pharmacology. 9: 1084. PMID 30319418 DOI: 10.3389/Fphar.2018.01084 |
0.685 |
|
| 2018 |
Franks LN, Ford BM, Fujiwara T, Zhao H, Prather PL. The tamoxifen derivative ridaifen-B is a high affinity selective CB receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. Toxicology and Applied Pharmacology. PMID 29906493 DOI: 10.1016/J.Taap.2018.06.009 |
0.449 |
|
| 2018 |
Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochemical and Biophysical Research Communications. PMID 29522717 DOI: 10.1016/J.Bbrc.2018.03.028 |
0.794 |
|
| 2018 |
Prather PL. Preface to DMR special edition 'Cannabinoid receptors and ligands: therapeutic drug development and abuse potential'. Drug Metabolism Reviews. 1-2. PMID 29378464 DOI: 10.1080/03602532.2018.1431657 |
0.418 |
|
| 2018 |
Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M. Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. Life Sciences. 192: 151-159. PMID 29191644 DOI: 10.1016/J.Lfs.2017.11.042 |
0.325 |
|
| 2017 |
Crowe MS, Wilson CD, Leishman E, Prather PL, Bradshaw HB, Banks ML, Kinsey SG. The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. British Journal of Pharmacology. PMID 28963716 DOI: 10.1111/Bph.14055 |
0.312 |
|
| 2017 |
Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of Structurally Novel G Protein Biased CB1 Agonists: Implications for Drug Development. Pharmacological Research. PMID 28838808 DOI: 10.1016/J.Phrs.2017.08.008 |
0.704 |
|
| 2017 |
Yadlapalli JSK, Dogra N, Walbaum AW, Wessinger WD, Prather PL, Crooks PA, Dobretsov M. Evaluation of Analgesia, Tolerance, and the Mechanism of Action of Morphine-6-O-Sulfate Across Multiple Pain Modalities in Sprague-Dawley Rats. Anesthesia and Analgesia. PMID 28489639 DOI: 10.1213/Ane.0000000000002006 |
0.339 |
|
| 2017 |
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends in Pharmacological Sciences. PMID 28162792 DOI: 10.1016/J.Tips.2016.12.003 |
0.668 |
|
| 2016 |
Franks LN, Ford BM, Prather PL. Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Frontiers in Pharmacology. 7: 503. PMID 28066250 DOI: 10.3389/Fphar.2016.00503 |
0.477 |
|
| 2016 |
Ford BM, Franks LN, Radominska-Pandya A, Prather PL. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. Plos One. 11: e0167240. PMID 27936172 DOI: 10.1371/Journal.Pone.0167240 |
0.461 |
|
| 2016 |
Yadlapalli JS, Ford BM, Ketkar A, Wan A, Penthala NR, Eoff RL, Prather PL, Dobretsov M, Crooks PA. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors. Pharmacological Research. PMID 27637375 DOI: 10.1016/J.Phrs.2016.09.012 |
0.39 |
|
| 2015 |
Anthony Jalin AM, Rajasekaran M, Prather PL, Kwon JS, Gajulapati V, Choi Y, Kim C, Pahk K, Ju C, Kim WK. Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity. Plos One. 10: e0141600. PMID 26517721 DOI: 10.1371/Journal.Pone.0141600 |
0.767 |
|
| 2015 |
Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE. Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacological Research. 102: 22-32. PMID 26361728 DOI: 10.1016/J.Phrs.2015.09.006 |
0.786 |
|
| 2014 |
Franks LN, Ford BM, Madadi NR, Penthala NR, Crooks PA, Prather PL. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. European Journal of Pharmacology. 737: 140-8. PMID 24858620 DOI: 10.1016/J.Ejphar.2014.05.007 |
0.483 |
|
| 2014 |
Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Pharmacology, Biochemistry, and Behavior. 124: 40-7. PMID 24857780 DOI: 10.1016/J.Pbb.2014.05.010 |
0.795 |
|
| 2014 |
Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sciences. 97: 45-54. PMID 24084047 DOI: 10.1016/J.Lfs.2013.09.017 |
0.686 |
|
| 2014 |
Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metabolism Reviews. 46: 72-85. PMID 24063277 DOI: 10.3109/03602532.2013.839700 |
0.763 |
|
| 2013 |
Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Science International. 233: 416-22. PMID 24314548 DOI: 10.1016/J.Forsciint.2013.10.002 |
0.771 |
|
| 2013 |
Prather PL, FrancisDevaraj F, Dates CR, Greer AK, Bratton SM, Ford BM, Franks LN, Radominska-Pandya A. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochemical and Biophysical Research Communications. 441: 339-43. PMID 24148245 DOI: 10.1016/J.Bbrc.2013.10.057 |
0.41 |
|
| 2013 |
Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: Implications for drug abuse liability and pain therapys Journal of Pharmacology and Experimental Therapeutics. 346: 350-361. PMID 23801678 DOI: 10.1124/Jpet.113.206003 |
0.804 |
|
| 2013 |
Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. Journal of Medicinal Chemistry. 56: 4537-50. PMID 23631463 DOI: 10.1021/Jm400268B |
0.637 |
|
| 2013 |
Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicology and Applied Pharmacology. 269: 100-8. PMID 23537664 DOI: 10.1016/J.Taap.2013.03.012 |
0.793 |
|
| 2013 |
Madadi NR, Penthala NR, Brents LK, Ford BM, Prather PL, Crooks PA. Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors. Bioorganic & Medicinal Chemistry Letters. 23: 2019-21. PMID 23466226 DOI: 10.1016/J.Bmcl.2013.02.025 |
0.754 |
|
| 2013 |
Choi IY, Ju C, Anthony Jalin AMA, Lee DI, Prather PL, Kim WK. Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury American Journal of Pathology. 182: 928-939. PMID 23414569 DOI: 10.1016/J.Ajpath.2012.11.024 |
0.364 |
|
| 2012 |
Koryakina Y, Jones SM, Cornett LE, Seely K, Brents L, Prather PL, Kofman A, Kurten RC. Effects of the β-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of β2-adrenergic receptors with N-terminal polymorphisms. Cell Biology International. 36: 1171-83. PMID 22938397 DOI: 10.1042/Cbi20120134 |
0.759 |
|
| 2012 |
Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 2174-84. PMID 22904561 DOI: 10.1124/Dmd.112.047530 |
0.816 |
|
| 2012 |
Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies Neuropharmacology. 63: 905-915. PMID 22771770 DOI: 10.1016/J.Neuropharm.2012.06.046 |
0.749 |
|
| 2012 |
Safe SH, Prather PL, Brents LK, Chadalapaka G, Jutooru I. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anti-Cancer Agents in Medicinal Chemistry. 12: 1211-20. PMID 22583404 DOI: 10.2174/187152012803833099 |
0.724 |
|
| 2012 |
Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Molecular Cancer Therapeutics. 11: 1421-31. PMID 22553354 DOI: 10.1158/1535-7163.Mct-12-0026 |
0.703 |
|
| 2012 |
Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chemical Research in Toxicology. 25: 825-7. PMID 22404317 DOI: 10.1021/Tx3000472 |
0.815 |
|
| 2012 |
Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity Biochemical Pharmacology. 83: 952-961. PMID 22266354 DOI: 10.1016/J.Bcp.2012.01.004 |
0.802 |
|
| 2012 |
Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 42: 139-56. PMID 21970716 DOI: 10.3109/00498254.2011.609570 |
0.808 |
|
| 2011 |
Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase i hydroxylated metabolites of the k2 synthetic cannabinoid jwh-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity Plos One. 6. PMID 21755008 DOI: 10.1371/Journal.Pone.0021917 |
0.823 |
|
| 2011 |
Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, ... Prather PL, et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine Analytical Chemistry. 83: 4228-4236. PMID 21506519 DOI: 10.1021/Ac2005636 |
0.608 |
|
| 2011 |
Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Molecular Interventions. 11: 36-51. PMID 21441120 DOI: 10.1124/Mi.11.1.6 |
0.758 |
|
| 2009 |
Prather PL, Seely KA, Levi MS. Notice of retraction. The Journal of Pharmacology and Experimental Therapeutics. 331: 1147. PMID 19940110 |
0.661 |
|
| 2009 |
Seely KA, Levi MS, Prather PL. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. The Journal of Pharmacology and Experimental Therapeutics. 330: 31-9. PMID 19359525 DOI: 10.1124/Jpet.109.151654 |
0.802 |
|
| 2009 |
Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radomińska-Pandya A, Moran JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1496-504. PMID 19339377 DOI: 10.1124/Dmd.109.026898 |
0.372 |
|
| 2007 |
Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Journal of Neurochemistry. 101: 87-98. PMID 17241118 DOI: 10.1111/J.1471-4159.2006.04346.X |
0.771 |
|
| 2005 |
Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. The Journal of Pharmacology and Experimental Therapeutics. 315: 828-38. PMID 16081674 DOI: 10.1124/Jpet.105.089474 |
0.782 |
|
| 2005 |
Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. The Journal of Pharmacology and Experimental Therapeutics. 314: 868-75. PMID 15901805 DOI: 10.1124/Jpet.105.085282 |
0.807 |
|
| 2004 |
Prather PL. Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors. Science's Stke : Signal Transduction Knowledge Environment. 2004: pe1. PMID 14722344 DOI: 10.1126/Stke.2152004Pe1 |
0.46 |
|
| 2002 |
Liu JG, Prather PL. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors. The Journal of Pharmacology and Experimental Therapeutics. 302: 1070-9. PMID 12183665 DOI: 10.1124/Jpet.102.035964 |
0.458 |
|
| 2002 |
Martin NA, Ruckle MB, VanHoof SL, Prather PL. Agonist, antagonist, and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective delta-opioid receptor ligand. The Journal of Pharmacology and Experimental Therapeutics. 301: 661-71. PMID 11961071 DOI: 10.1124/Jpet.301.2.661 |
0.485 |
|
| 2001 |
Liu JG, Ruckle MB, Prather PL. Constitutively active mu-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2,N-MePhe4,Gly-ol5]enkephalin. The Journal of Biological Chemistry. 276: 37779-86. PMID 11500514 DOI: 10.1074/Jbc.M106104200 |
0.462 |
|
| 2001 |
Liu JG, Prather PL. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Molecular Pharmacology. 60: 53-62. PMID 11408600 DOI: 10.1124/Mol.60.1.53 |
0.418 |
|
| 2001 |
Martin NA, Prather PL. Interaction of co-expressed mu- and delta-opioid receptors in transfected rat pituitary GH(3) cells. Molecular Pharmacology. 59: 774-83. PMID 11259622 DOI: 10.1124/Mol.59.4.774 |
0.449 |
|
| 2000 |
Ho BY, Stadnicka A, Prather PL, Buckley AR, Current LL, Bosnjak ZJ, Kwok WM. Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. Endocrinology. 141: 1675-85. PMID 10803576 DOI: 10.1210/Endo.141.5.7454 |
0.315 |
|
| 1999 |
McCormack K, Prather P, Chapleo C. Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain. 78: 79-98. PMID 9839818 DOI: 10.1016/S0304-3959(98)00146-8 |
0.383 |
|
| 1996 |
Claude PA, Wotta DR, Zhang XH, Prather PL, McGinn TM, Erickson LJ, Loh HH, Law PY. Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. Proceedings of the National Academy of Sciences of the United States of America. 93: 5715-9. PMID 8650158 DOI: 10.1073/pnas.93.12.5715 |
0.325 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2020 |
Yang JF, Williams AH, Penthala NR, Prather PL, Crooks PA, Zhan CG. Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands. Acs Chemical Neuroscience. PMID 32997485 DOI: 10.1021/acschemneuro.0c00551 |
0.288 |
|
| 2005 |
Tiwari MM, Prather PL, Mayeux PR. Mechanism of bradykinin-induced Ca2+ mobilization in murine proximal tubule epithelial cells. The Journal of Pharmacology and Experimental Therapeutics. 313: 798-805. PMID 15665141 DOI: 10.1124/Jpet.104.080408 |
0.286 |
|
| 2015 |
Yadlapalli J, Dogra N, Ford B, Albayati Z, Penthala N, Prather P, Dobretsov M, Crooks P. (434) Analgesic profile of morphine 6-O-sulfate sodium: a mixed mu/delta agonist in the treatment of diabetic neuropathic pain The Journal of Pain. 16: S84. DOI: 10.1016/J.Jpain.2015.01.353 |
0.286 |
|
| 2013 |
Ju C, Hwang S, Cho GS, Kondaji G, Song S, Prather PL, Choi Y, Kim WK. Differential anti-ischemic efficacy and therapeutic time window of trans- and cis-hinokiresinols: stereo-specific antioxidant and anti-inflammatory activities. Neuropharmacology. 67: 465-75. PMID 23287539 DOI: 10.1016/J.Neuropharm.2012.12.006 |
0.285 |
|
| 1992 |
Prather PL, Forster MJ, Lal H. Learning and memory-enhancing effects of Ro 15-4513: A comparison with flumazenil Neuropharmacology. 31: 299-306. PMID 1630596 DOI: 10.1016/0028-3908(92)90180-W |
0.278 |
|
| 1995 |
Prather PL, McGinn TM, Claude PA, Liu-Chen LY, Loh HH, Law PY. Properties of a kappa-opioid receptor expressed in CHO cells: interaction with multiple G-proteins is not specific for any individual G alpha subunit and is similar to that of other opioid receptors. Brain Research. Molecular Brain Research. 29: 336-46. PMID 7609621 DOI: 10.1016/0169-328X(94)00264-F |
0.263 |
|
| 2021 |
Fulo HF, Shoeib A, Cabanlong CV, Williams AH, Zhan CG, Prather PL, Dudley GB. Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists. Journal of Medicinal Chemistry. PMID 33887913 DOI: 10.1021/acs.jmedchem.1c00442 |
0.26 |
|
| 2021 |
Shoeib AM, Yarbrough AL, Ford BM, Franks LN, Urbaniak A, Hensley LL, Benson LN, Mu S, Radominska-Pandya A, Prather PL. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. Life Sciences. 285: 119993. PMID 34592231 DOI: 10.1016/j.lfs.2021.119993 |
0.247 |
|
| 2022 |
Shoeib AM, Benson LN, Mu S, MacMillan-Crow LA, Prather PL. Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death. International Journal of Molecular Sciences. 23. PMID 35328467 DOI: 10.3390/ijms23063049 |
0.232 |
|
| 2018 |
Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M. Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome? Neuroscience Letters. 673: 24-27. PMID 29490230 DOI: 10.1016/J.Neulet.2018.02.054 |
0.216 |
|
| 1995 |
Forster MJ, Prather PL, Patel SR, Lal H. The benzodiazepine receptor inverse agonist RO 15-3505 reverses recent memory deficits in aged mice Pharmacology, Biochemistry and Behavior. 51: 557-560. PMID 7667387 DOI: 10.1016/0091-3057(95)00063-3 |
0.214 |
|
| 1995 |
Chakrabarti S, Prather PL, Yu L, Law PY, Loh HH. Expression of the mu-opioid receptor in CHO cells: ability of mu-opioid ligands to promote alpha-azidoanilido[32P]GTP labeling of multiple G protein alpha subunits. Journal of Neurochemistry. 64: 2534-43. PMID 7760033 DOI: 10.1046/j.1471-4159.1995.64062534.x |
0.213 |
|
| 2014 |
Wang J, Zheng J, Kulkarni A, Wang W, Garg S, Prather PL, Hauer-Jensen M. Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner. Digestive Diseases and Sciences. 59: 2693-703. PMID 24848354 DOI: 10.1007/S10620-014-3212-5 |
0.212 |
|
| 1991 |
Prather PL, Rezazadeh SM, Jianping C, Lal H, Martin MW. Modulation of benzodiazepine agonist and inverse-agonist receptor binding by GABA during ethanol withdrawal Progress in Neuropsychopharmacology and Biological Psychiatry. 15: 921-934. PMID 1662404 DOI: 10.1016/0278-5846(91)90019-W |
0.196 |
|
| 2022 |
Crosby SV, Ahmed IY, Osborn LR, Wang Z, Schleiff MA, Fantegrossi WE, Nagar S, Prather PL, Boysen G, Miller GP. Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes. Metabolites. 12. PMID 36005645 DOI: 10.3390/metabo12080773 |
0.194 |
|
| 2020 |
Pinson AO, Pouncey DL, Schleiff MA, Fantegrossi WE, Prather PL, Radominska-Pandya A, Boysen G, Miller GP. Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules (Basel, Switzerland). 25. PMID 33092129 DOI: 10.3390/molecules25204820 |
0.181 |
|
| 1993 |
Bhadra S, Prather PL, Elkhayat I, Benjamin D, Harris CM, Lal H. Anxiogenic effect of disulfiram evaluated in an animal model. Journal of Studies On Alcohol. 54: 5-10. PMID 8394957 DOI: 10.15288/JSA.1993.54.5 |
0.173 |
|
| 1993 |
Lal H, Prather PL, Rezazadeh SM. Potential role of 5HT(1C) and/or 5HT2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal Alcoholism: Clinical and Experimental Research. 17: 411-417. PMID 8488986 DOI: 10.1111/J.1530-0277.1993.TB00785.X |
0.171 |
|
| 1993 |
Rezazadeh SM, Prather PL, Lal H. Sensitization to 5-HT1C receptor agonist in rats observed following withdrawal from chronic ethanol. Alcohol (Fayetteville, N.Y.). 10: 281-3. PMID 8397879 DOI: 10.1016/0741-8329(93)90006-A |
0.161 |
|
| 1991 |
Lal H, Prather PL, Rezazadeh SM. Anxiogenic behavior in rats during acute and protracted ethanol withdrawal: Reversal by buspirone Alcohol. 8: 467-471. PMID 1781924 DOI: 10.1016/S0741-8329(91)90153-N |
0.136 |
|
| 1992 |
Rezazadeh SM, Prather PL, Emmett-Oglesby MW, Lal H. Evaluation of anxiolytic action of ondansetron in rats during withdrawal from chronic chlordiazepoxide Annals of the New York Academy of Sciences. 654: 472-473. PMID 1352955 DOI: 10.1111/j.1749-6632.1992.tb26003.x |
0.085 |
|
| Hide low-probability matches. |